Compare Meta Platforms Inc (META) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

META stock trades at $653.33, up 1.13% in the last session, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, including Q1 2026 EPS of $10.44 versus $6.70 expected. Revenue grew to $201.0 billion in 2025, with a net income margin of 30.08%. Recent news highlights the launch of its Muse Spark AI model and a $21 billion deal with CoreWeave, driving positive sentiment.

Outlook remains positive with a consensus price target of $817.32, implying 25% upside. Key opportunities include AI monetization and sustained revenue growth, while risks involve regulatory lawsuits and high capital expenditures. Analyst consensus is strongly bullish with 79% buy ratings, but investors should monitor legal developments and competitive pressures in the social media and AI sectors.

Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.

Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.